SEC Form 4 · accession 0001140361-15-038993
OncoMed Pharmaceuticals Inc · OMED
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alicia J. Hager
Officer — VP & General Counsel
Period of report
Oct 27, 2015
Accepted (ET)
Oct 29, 2015 · 7:49 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001302573
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Oct 27, 2015 | M | 5,400 | $3.42 | A | 20,400 | D | |
| Common StockF2 | Oct 27, 2015 | S | 5,400 | $21.00 | D | 15,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $3.42 | Oct 27, 2015 | M | 5,400 | D | — | Jul 22, 2018 | Common Stock | 5,400 | 8,452 | D |
Explanation of responses
- F1Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 23, 2015.
- F2Includes 15,000 restricted stock units. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) restricted stock unit.
- F3The option is fully vested and exercisable, subject to a limitation of 175,438 shares that can be issued to a single grantee in a 12-month period upon the exercise of awards under the Issuer's 2004 Stock Incentive Plan.